Biovista Personalized Medicine and Diginova to deliver next generation AI-driven doctor/patient support in a deal that can generate over $5 Billion.

CHARLOTTESVILLE, Va. and DUBAI, UAE, Sept. 15, 2021 /PRNewswire/ -- Biovista Personalized Medicine and Diginova Health Solutions today announced their deal to deliver augmented intelligence (AI)-driven personalized medicine analytics to over a quarter of a billion patients in Asia, starting in the MENA region. Diginova will offer Biovista Personalized Medicine's market-leading AI Health Shield^TM analytics direct-to-consumer, where the consumers are doctors, patients, their family caregivers, and national/regional health systems.

"We are excited to partner with Diginova on bringing our AI Health Shield^TM to a major part of the world," said Aris Persidis, Biovista Personalized Medicine's Managing Director. "Diginova is excellent at integrating the right health solutions for patients and doctors and has an innovation-led vision for the future of healthcare that is aligned with ours," he continued.

"Outside of cancer, there were no AI-based solutions that could deeply understand patient data, including the use of data to understand existing therapies versus unanticipated ones, until the arrival of Biovista Personalized Medicine's AI Health Shield^TM," said Sarper Tanli, CEO of Diginova. "Biovista Personalized Medicine helps us deliver high quality-analytics to our consumers for any real-world clinical scenarios they may be facing. We see the AI Health Shield^TM as a real disruptor in the delivery of data-driven healthcare services," he added.

"We see this deal as generating potentially over $5 billion in new AI-driven service revenues over its current iteration and lifetime," said Persidis, "helping us continue to engineer better healthcare for everybody's future," he added.

About Biovista Personalized Medicine's AI Health Shield^TM:  It compares a patient's current diagnosis and treatment program against the many millions of evidence-based research reports published annually in scientific journals. It then recommends either extensions or replacements of the standard of care when the latter fails. Such augmented intelligence-supported analytics help physicians to adjust treatment plans and medications as well as pro-actively "think differently" for patients in need. Going beyond AI-based systems focused primarily in cancer as offered by competing personalized medicine companies, Biovista Personalized Medicine's AI Health Shield^TM was designed from the start to be disease/therapy agnostic.

About Biovista Personalized Medicine: The company is a wholly-owned subsidiary of Biovista, Inc., the award-winning pioneer in AI-driven drug repositioning and personalized medicine. Biovista Personalized Medicine's focus is the delivery of the class-leading AI-Health Shield^TM to consumers, patients, caregivers, doctors and health systems.

About Diginova: Based in the UAE, Diginova advances evidence-based technologies and digital care models to treat a broad spectrum of conditions, both chronic and otherwise. Diginova's multi-functional digital health platforms include, but are not limited to therapeutic care, diagnostics, HCP upskilling and more.

Further information:
For BPM: [email protected]
For Diginova: [email protected]

SOURCE Biovista

Related Links

http://www.biovista.com